Search - tctmd.com

Displaying 41 - 60 of 414

Sort: Relevancy | Date

News Daily News

Bivalirudin’s Bleeding Benefits Dampened by PCI Advances, Analysis Shows

Todd Neale

December 14, 2015

News Conference News AHA 2015

Varenicline Helps ACS Patients Quit Smoking, But Effect Wanes

Todd Neale

November 12, 2015

News Daily News

药代动力学研究确认了吗啡对替卡格雷的负面影响

Shelley Wood

October 29, 2015

News Daily News

Un Estudio Farmacocinético Confirma Preocupantes Efectos de la Morfina sobre Ticagrelor

Shelley Wood

October 29, 2015

News Daily News

Morphine’s Worrisome Effects on Ticagrelor Affirmed in Pharmacokinetic Study

Shelley Wood

October 29, 2015

Presentation TCT 2015

TCT 112: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention The REsponsiveness To CLOpidogrel And StEnt Thrombosis (RECLOSE) 3 Study

Presenter: Steven R. Bailey, Patrick W. Serruys, Renato Valenti

October 15, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

Presentation TCT 2015

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prasugrel Is Just as Good!

Presenter: Eric Boersma, E. Magnus Ohman, Giuseppe Biondi-Zoccai

October 12, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Presenter: John A. Bittl, E. Magnus Ohman, Jorge F. Saucedo

October 11, 2015

Presentation TCT 2015

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Presenter: John A. Bittl, E. Magnus Ohman, Christoph A. Kaiser

October 11, 2015

Presentation TCT 2015

Lessons From the TAXUS Liberté/Prasugrel Substudy

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Presenter: C. Michael Gibson, Marco Valgimigli, Sigmund Silber

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Daily News

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

Yael L. Maxwell

October 09, 2015

News Daily News

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

Yael L. Maxwell

October 09, 2015

News Daily News

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

Caitlin E. Cox

October 06, 2015

News Daily News

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Caitlin E. Cox

October 06, 2015

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

News Daily News

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

L.A. McKeown

September 21, 2015

Advertisement

Bivalirudin’s Bleeding Benefits Dampened by PCI Advances, Analysis Shows

Varenicline Helps ACS Patients Quit Smoking, But Effect Wanes

药代动力学研究确认了吗啡对替卡格雷的负面影响

Un Estudio Farmacocinético Confirma Preocupantes Efectos de la Morfina sobre Ticagrelor

Morphine’s Worrisome Effects on Ticagrelor Affirmed in Pharmacokinetic Study

TCT 112: Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention The REsponsiveness To CLOpidogrel And StEnt Thrombosis (RECLOSE) 3 Study

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Debate: What Is the Optimal ADP-Antagonist Preloading Approach in STEMI? Prasugrel Is Just as Good!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? No, the Risks Are Real and There Is No Evidence for Benefit!

Debate: Should Prasugrel and Ticagrelor Be Used in a Substantial Number of Patients With Stable CAD? Yes, the Benefits Outweigh the Risks!

Lessons From the TAXUS Liberté/Prasugrel Substudy

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Subestudio ADAPT-DES: Los Cambios de la Práctica podrían disminuir aún más los ya bajos índices de trombosis del stent

ADAPT-DES Substudy: Practice Changes May Decrease Already Low Stent Thrombosis Rates Even Further

No Interplay Between Access Site, Cangrelor Effects in PCI Patients

No hay interacción entre el punto de acceso y los efectos del Cangrelor en pacientes con PCI

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content